In re: Nexium: Judge Young Denies Defendants’ Motions for a Directed Verdict

Patterson Belknap Webb & Tyler LLP
Contact

Last week, the Nexium district court ruled on defendants’ motions seeking judgment as a matter of law.  As we previously reported in several earlier posts (click here to see our prior coverage), In re: Nexium is the first pay-for-delay case to go to trial since the Supreme Court’s Federal Trade Commission v. Actavis decision.

The Nexium plaintiffs have asserted a novel pay-for-delay theory: that AstraZeneca agreed to accept a reduced settlement payment from Teva in a separate patent infringement litigation involving Prilosec in exchange for Teva’s agreement to delay its launch of Nexium’s generic competitor.  According to plaintiffs, this reduced payment constitutes a large, unexplained payment within the meaning of Actavis.  The theory involves not only Teva but also generic manufacturer Ranbaxy, which also settled a patent infringement case involving generic Nexium.

Although focusing on that novel issue is interesting for blog posts, in their motions defendants smartly focused the court’s attention on the more run-of-the-mill questions facing the court: Can plaintiffs show conspiracy, causation and antitrust injury?  After all, steering a district court towards a well-trodden path on these issues is much easier than convincing the court to take the bigger leap on a novel question: Does the alleged consideration here fall within Actavis?  Defendants probably thought that there was a chance that Judge Young might latch on to one of these issues and resolve the case on a traditional antitrust issue or two. However, Judge Young chose not to engage in a lengthy discussion on any of these issues and, with the exception of a motion addressed to an alleged conspiracy between Teva and Ranbaxy,  simply denied defendants’ motions saying that there are several “prudential reasons” why the case should go to a jury, and noted that concerns about “jumping too quickly” prompted him to deny the directed verdict bids.

It therefore appears that we will see a jury verdict on the novel issue raised in In re: Nexium  and probably post-verdict rulings by district and appellate courts.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP
Contact
more
less

Patterson Belknap Webb & Tyler LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide